Epigenetic loss of CDH1 correlates with multidrug resistance in human hepatocellular carcinoma cells

Biochemical and Biophysical Research Communications

Volumn 422, Issue 4, 2012, Pages 739-744

  Jiang, Lei ^a   Chan, Judy Yuet Wa ^a   Fung, Kwok Pui ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

CDH1; FYN; Multidrug resistance; Promoter hypermethylation

Indexed keywords

COMPLEMENTARY DNA; DOXORUBICIN; GLYCOPROTEIN P; METHOTREXATE; PROTEIN KINASE FYN; UVOMORULIN; VINCRISTINE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; DNA METHYLATION; DRUG UPTAKE; EPIGENETICS; GENE SILENCING; GENETIC CORRELATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTO ONCOGENE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CADHERINS; CARCINOMA, HEPATOCELLULAR; DNA METHYLATION; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; EPIGENOMICS; GENES, TUMOR SUPPRESSOR; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; P-GLYCOPROTEIN; PROMOTER REGIONS, GENETIC;

EID: 84862295159     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.05.072     Document Type: Article

References (22)

1. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2(1):48-58.
2. Lage H. An overview of cancer multidrug resistance. a still unsolved problem. Cell Mol. Life Sci. 2008, 65(20):3145-3167.
3. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53:615-627.
4. Doyle L.A., Ross D.D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003, 22(47):7340-7358.
5. Ibrahim N., He L., Leong C.O., et al. BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma. Cancer Res. 2010, 70(18):7155-7165.
6. Stavrovskaya A.A. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc) 2000, 65(1):95-106.
7. Gifford G., Paul J., Vasey P.A., et al. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin. Cancer Res. 2004, 10(13):4420-4426.
8. Glasspool R.M., Teodoridis J.M., Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br. J. Cancer 2006, 94(8):1087-1092.
9. Crea F., Nobili S., Paolicchi E., et al. Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies. Drug Resist Updat 2011, 14(6):280-296.
10. Huo H., Magro P.G., Pietsch E.C., et al. Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance. Cancer Res. 2010, 70(21):8726-8735.
11. McDonald O.G., Wu H., Timp W., et al. Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nat. Struct. Mol. Biol. 2011, 18(8):867-874.
12. Tsuchiya B., Sato Y., Kameya T., et al. Differential expression of N-cadherin and E-cadherin in normal human tissues. Arch. Histol. Cytol. 2006, 69(2):135-145.
13. Chan J.Y., Chu A.C., Fung K.P. Inhibition of P-glycoprotein expression and reversal of drug resistance of human hepatoma HepG2 cells by multidrug resistance gene (mdr1) antisense RNA. Life Sci. 2000, 67(17):2117-2124.
14. Bui-Xuan N.H., Tang P.M., Wong C.K., et al. Pheophorbide a: a photosensitizer with immunostimulating activities on mouse macrophage RAW 264.7 cells in the absence of irradiation. Cell Immunol. 2011, 269(1):60-67.
15. Wang J., Chan J.Y., Fong C.C., et al. Transcriptional analysis of doxorubicin-induced cytotoxicity and resistance in human hepatocellular carcinoma cell lines. Liver Int. 2009, 29(9):1338-1347.
16. Weng Z., Xin M., Pablo L., et al. Protection against anoikis and down-regulation of cadherin expression by a regulatable beta-catenin protein. J. Biol. Chem. 2002, 277(21):18677-18686.
17. Kang H.G., Jenabi J.M., Zhang J., et al. E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res. 2007, 67(7):3094-3105.
18. Kumar S., Park S.H., Cieply B., et al. A pathway for the control of anoikis sensitivity by E-cadherin and epithelial-to-mesenchymal transition. Mol. Cell Biol. 2011, 31(19):4036-4051.
19. dit Faute M.A., Laurent L., Ploton D., et al. Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7 a human breast cancer cell line, and its multidrug resistant variant. Clin Exp Metastasis 2002, 19(2):161-168.
20. Arumugam T., Ramachandran V., Fournier K.F., et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009, 69(14):5820-5828.
21. Saito Y.D., Jensen A.R., Salgia R., et al. Fyn: a novel molecular target in cancer. Cancer 2010, 116(7):1629-1637.
22. Grosso S., Puissant A., Dufies M., et al. Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors. Mol. Cancer Ther. 2009, 8(7):1924-1933.